Study design: a randomized, blinded, parallel, positive-controlled, multicenter clinical study enrolling 251 patients aged 18-70 years with STEMI within 12 h of onset
Primary efficacy: The patency rate of Reflow™ (rhTNK-tPA) 16 mg for 90 min infarcted blood vessels was significantly higher than that of recombinant human tissue-type plasminogen activator (rt-PA) (p<0.05)
Study design: a randomized, open, parallel, positive-controlled, non-inferiority trial enrolling 823 patients at 115 participating centers
The primary endpoint showed that the incidence of MACCE at 30 days was similar or even slightly lower for mefloquine compared to alteplase.
The safety results show that the risk of bleeding is low and the safety profile of Mafenox is not comparable to that of rt-PA.
Study design: a combined prospective and retrospective, open-ended, single-group, multicenter IDM design with 1010 active cases enrolled.
The results showed that gingival bleeding (3.9%) was the most common adverse event, while other bleeding events were occasional (≤1%), the incidence of death (3.9%) and cerebral hemorrhage (0.3%) were not above the lower limit of the epidemiological study level, and no new serious risk signals were found for MDFL.
Tenecteplase* is currently the most convenient thrombolytic drug with the highest patency rate, especially suitable for primary hospitals and pre-hospital thrombolysis.
Fibrin-specific thrombolytic drug Tenecteplase* is recommended (1, B)
The specific plasminogen activators have a high thrombolysis patency rate and are more suitable for thrombolytic therapy. Tenecteplase (rhTNK-tPA): 16mg/pc; Dilute with 3ml of water for injection and inject intravenously within 5-10s. Single dose and easy to use.
Instructions for use of Tenecteplase independently developed in China: on the basis of intravenous heparin treatment, dilute 16 mg of Tenecteplase with 3 ml of sterile water for injection, and inject intravenously within 5-10s.
It is recommended to prioritize specific plasminogen activators, and the usage of commonly used thrombolytic drugs is: rhTNK-tPA 16mg/pc - Dilute with 3ml of water for injection and inject intravenously within 5-10s. It has a high patency rate, single intravenous injection, and is easy to use.
For patients with suspected or confirmed COVID-19 and complicated with STEMI, if there are no contraindications to thrombolysis, thrombolysis is preferred in the isolation ward, and the third-generation thrombolytic drugs are recommended. (rhTNK-tPA is a third-generation specific thrombolytic drug)
*Reflow (rhTNK-tPA) is the only Tenecteplase currently marketed in China
*Prescription drugs should be used under the guidance of professional physicians. For product details, refer to the Package Insert.
